CD8A and melanoma: In this regard, it is interesting to note that the knockdown of Irg1 reduces melanoma growth, inhibits the immune‐suppressive activities of MDSCs, promotes anti‐tumor immunity of CD8+ T cells, and enhances the efficacy of anti‐PD‐1 treatment [146].